Clinical Research Directory

Inclusion Criteria: * Age 18 to 70 years. * Diagnosis of Crohn's disease for at least 3 months before screening, based on clinical manifestations and endoscopic and/or imaging findings, with histopathological support. * Presence of a small bowel stricture that prevents passage of the enteroscope. * Partial intestinal obstruction, meeting the following criteria: 1. Clinical manifestations of partial intestinal obstruction; 2. Small bowel stricture identified by endoscopy (with a lumen narrower than the distal end of the enteroscope) or computed tomography enterography (CTE); and 3. Marked dilation of the bowel lumen proximal to the stricture demonstrated by enteroscopy or CTE. * Written informed consent and any required privacy authorization signed and dated by the participant or the participant's legally authorized representative, as applicable, before initiation of study procedures. * Female participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use adequate conventional contraception throughout the study period, beginning at the time of signing the informed consent form. Exclusion Criteria: * Anastomotic stricture. * Deep or large ulceration at the stricture site. * Marked angulation or sharp bending at the stricture site. * An absolute indication for surgical treatment, including acute perforation, major bleeding that cannot be managed medically or endoscopically, intra-abdominal abscess, small bowel fistula, or malignancy. * Inability to tolerate anesthesia, enteroscopy, or surgical treatment because of conditions such as cardiac or pulmonary failure or severe coagulation disorders. * Evidence of active infection during the screening period. * Active tuberculosis, including findings suspicious for pulmonary tuberculosis on chest radiography performed within 3 months before Week 0. * Any confirmed congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection or organ transplantation. * A clinically significant infection, such as pneumonia or pyelonephritis, within 30 days before screening, or an ongoing chronic infection. * Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematologic, coagulation, immune, endocrine/metabolic, or other medical condition that, in the investigator's opinion, could interfere with study results or compromise participant safety. * History of malignancy. * Any of the following laboratory abnormalities during screening: 1. Hemoglobin \<5 g/dL; 2. White blood cell count \<3 × 10\^9/L; 3. Platelet count \<100 × 10\^9/L or \>1200 × 10\^9/L; 4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN); or 5. Serum creatinine \>2 times the ULN. * Inability to attend all required study visits or comply with study procedures. * Female participants who are pregnant, plan to become pregnant before or during study participation, or plan to donate ova during this period. * Participants who are coerced into consenting to study participation. * Any other condition that, in the investigator's opinion, makes the participant unsuitable for endoscopic or surgical treatment.